Domov › Burkittov limfom › Havaji
Klinične študije za Burkittov limfom v Havaji
5 študij za Burkittov limfom išče udeležence na lokacijah v Havaji.
Mesta v Havaji
Uradno besedilo študije (angleško)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Kapiolani Medical Center for Women and Children, Honolulu
Vključevanje udeležencevFaza 2
366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Straub Clinic and Hospital, Honolulu
- Kapiolani Medical Center for Women and Children, Honolulu
- Pali Momi Medical Center, ‘Aiea
Vključevanje udeležencevFaza 3
Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Kapiolani Medical Center for Women and Children, Honolulu
Vključevanje udeležencevFaza 2
365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Kapiolani Medical Center for Women and Children, Honolulu
Vključevanje udeležencevFaza 2
Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Kapiolani Medical Center for Women and Children, Honolulu
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.